Aptose Biosciences Культура компании

Mr. Gregory K. Chow, also known as Greg, CPA, MBA, BA has been the Chief Financial Officer of Aptose Biosciences Inc. since December 2, 2013 and has been its Senior Vice President since April 10, 2014. Mr. Chow serves as Principal Accounting Officer at Aptose Biosciences Inc. He served as the Managing Director and led the Private Placements team in the Life Sciences Investment Banking Group at Wedbush Securities. Prior to joining Wedbush, he served as a Director in the Private Placements/Equity Capital Markets Group at RBC Capital Markets, where he led the life science private capital activities. He served as a Vice President in the Private Placement group, based in San Francisco office of RBC Capital Markets LLC since April 2006. His transactional experience covers a broad range of equity and equity-linked financings that include Initial Public Offerings, Follow-Ons, Confidentially Marketed Public Offerings, Registered Directs, Private Investment in Public Equities (PIPEs) and private placements for private companies. Prior to RBC, he directed the Private Capital Group at Wells Fargo Securities and was a Senior Auditor at BDO Seidman, LLP. He is a Certified Public Accountant (Inactive) in the State of California. He holds an MBA in Finance from the Wharton School at the University of Pennsylvania and a BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.

Dr. Stephen B. Howell, also known as Steve, MD, Ph.D. has been Chief Medical Officer at Aptose Biosciences Inc. since September 8, 2014. Dr. Howell is a Co-Founder of Targa Therapeutics Corp. and serves as its Chief Medical Consultant. Dr. Howell co-founded Beacon Laboratories in 1995. He has been Director of the Cancer Pharmacology Program of the UCSD Cancer Center since 2006. Dr. Howell has been a Professor of Medicine at the University of California, San Diego since 1977; is a Program Leader of the Cancer Pharmacology Program at the UCSD Cancer Center; and Associate Director for Clinical Research at University of California, San Diego. He also directs the Clayton Foundation Drug Resistance Laboratory at the UCSD Cancer Center. Dr. Howell founded DepoTech, Inc. and served as a member of its board of directors from 1989 to 1999. He serves as Scientific Advisor of Weifa ASA. He serves as Director of the Cancer Therapeutics Training Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. Dr. Howell served as the Senior Medical Advisor of Pacira Pharmaceuticals Inc. Dr. Howell was a Founder and Senior Vice President of Medical Affairs at Pacira Pharmaceuticals Inc. from 1987 to 1995. He founded Targa Pharmaceuticals in 2003 and serves as its Director and Medical Director. Dr. Howell served as Chairman of Clinical Advisory Board at PlasmaTech Biopharmaceuticals, Inc. He has been an Independent Director of Abeona Therapeutics Inc. formerly known as PlasmaTech Biopharmaceuticals, Inc. since 1996. Dr. Howell serves as a Member of Clinical Advisory Board at Biovex Ltd. He served as a Member of Scientific Advisory Board at Cylene Pharmaceuticals, Inc. He serves as Scientific Advisor of Clavis Pharma AS. He served as a Member of Clinical Advisory and Data Safety Monitoring Board of BioVex, Inc. He has technical expertise and strong commitment to promoting and advancing innovation in the healthcare industry. He serves as a Director of Angstrom Pharmaceuticals. Dr. Howell serves as a Member of Scientific Advisory Board of Xenova Group PLC. He served as a Director of Repros Therapeutics Inc. from May 2009 to September 28, 2009. He served as a Director of Matrix Pharmaceutical Inc. from February 2000 to 2002. Dr. Howell served as a Member of board of Directors of Pacira Pharmaceuticals Inc. from December 1989 to 1999. He served as a Director of Beacon Laboratories. He served on the National Research Council of the American Cancer Society and is on the editorial boards of multiple medical journals. Dr. Howell is a board-certified medical oncologist. He served as Chairman and Member of Scientific Advisory Board of Apricus Biosciences, Inc., since April 2010. He serves as Member of Advisory Board at Inhibrx LLC. Dr. Howell is a member of the Committee on Experimental Medicine of the Gynecologic Oncology Group. Dr. Howell is a member of numerous societies, including the American Association for Cancer Research and the American Society of Clinical Oncology. Acknowledged as a leading world expert in the field of cancer therapeutics, Dr. Howell has written extensively on the subject, authoring several books and over 280 articles. Dr. Howell is a recipient of the Milken Family Medical Foundation Award for Outstanding Work in the Field of Cancer Research and has been listed in The Best Doctors in America since 1990. He is a presidential citation from the American Head and Neck Society and a Fogarty Senior International Fellowship. He completed his residency at the Massachusetts General Hospital and the University of California, San Francisco, research training at the National Institutes of Health and medical oncology specialty training at the Dana Farber Cancer Institute. Dr. Howell received his AB in biology from the University of Chicago and his MD from Harvard Medical School. Dr. Howell also holds an honorary M.D. from the University of Goteborg, Sweden.

Denis Burger serves as the Lead Director of Aptose Biosciences, Inc.. Denis started at Aptose Biosciences, Inc. in March of 2009. Denis currently resides in Portland, Oregon Area.